Navigation Links
CEO to Address Los Angeles Business Leaders About Developing Pandemic and Business Continuity Plans
Date:10/29/2008

U.S. pharmaceuticals business, visit our website http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at http://www.RocheExchange.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Capella University Launches PhD in Counselor Education and Supervision : The new degree program, one of few available online, addresses growing need for counseling faculty and supervisors
2. Pilot Program Successfully Addresses Mental Health Issues in Pennsylvanias Children
3. Intimacy and Sexuality After Cancer: Questions Answered and Concerns Addressed
4. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
5. Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Oct. 25-29
6. Missouri Firms New Ventilator Design Addresses Serious Homeland Security Issue
7. VOICES Report Tracks State Progress and Trends in Addressing Childrens Critical Needs
8. AVMA Addresses Livestock Health Issues Before U.S. Congress
9. AST to Address Human Resources Groups Nationwide to Encourage them to Adopt a Paid Leave Plan for Organ Donors
10. Maternity Care Doctors to Call for Renewal of MCARE Abatement Fund, Address Growing Shortage of Maternity Care Physicians
11. WellPoints Dr. Alan Rosenberg to Address Industrys Top Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Humans damaging the oceans 9411 1Humans damaging the oceans 9411 2Humans damaging the oceans 9411 3Bizarre walking bat has ancient heritage 9408 1Bizarre walking bat has ancient heritage 9408 2Organic food not nutritionally better than conventionally produced food 9405 1Organic food not nutritionally better than conventionally produced food 9405 2